Design and synthesis of new theranostic agents for near-infrared imaging of β-amyloid plaques and inhibition of β-amyloid aggregation in Alzheimer's disease
Source abstract
Abstract
Abstract The presence of amyloid plaques predisposes clinical symptoms of cognitive impairment, which occurs much earlier than other clinical symptoms and plays a crucial role in the neuropathology of AD. Thus, developing probes for Aβ species imaging could be used for early diagnosis of AD, and blocking the initial steps of Aβ aggregation with small molecules has emerged as a valid disease-modifying therapy for Aβ. Herein, we report the design, synthesis and evaluation of a series of new theranostic agents, which can simultaneously perform near infra-red imaging of Aβ plaques, prevent self-aggregation of Aβ monomer, disaggregate preformed Aβ fibrils and play a protective effect on the toxicity of human neuroblastoma cells (SHSY5Y) induced by Aβ 1–42 . Most of these probes displayed maximum emission in PBS (>650 nm), which falls in the good range for NIRF probes. Importantly, these probes are found to have a high binding affinity toward Aβ aggregates, to exhibit a large fluorescence enhancement upon interaction with Aβ aggregates accompanied by a blueshift in the emission spectra of 20–40 nm and to show an excellent targeting ability for Aβ plaques in slices of brain and eye containing retina tissue from double transgenic mice. These molecules show a promising potential as theranostic agents for the diagnosis and therapy of AD.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Alzheimer's disease research and treatments · Cholinesterase and Neurodegenerative Diseases · Computational Drug Discovery Methods
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (30)
Show source-provided references
1. Alzheimer's disease: the amyloid cascade hypothesis10.1126/science.1566067 ↗
2. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics10.1126/science.1072994 ↗
3. The β-amyloid hypothesis in Alzheimer's disease: seeing is believing10.1021/ml300058m ↗
4. Molecular determinants of amyloid deposition in Alzheimer's disease: conformational studies of synthetic betaprotein fragments10.1021/bi00463a003 ↗
5. Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths10.1016/S0006-3495(94)80591-0 ↗
6. Amyloid beta-protein (Abeta) assembly: abeta 40 and Abeta 42 oligomerize through distinct pathways10.1073/pnas.222681699 ↗
7. Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease10.1038/aps.2011.14 ↗
8. Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability10.1523/JNEUROSCI.5098-09.2010 ↗
9. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability10.1074/jbc.M201750200 ↗
10. Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced dysfunction10.1042/BST0351219 ↗
11. Soluble amyloid-beta peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo10.1093/brain/awn174 ↗
12. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease10.1016/j.molmed.2007.12.002 ↗
13. Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease10.2174/156720509790147070 ↗
14. Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors10.1016/j.pneurobio.2009.01.001 ↗
15. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options10.2174/157015909787602823 ↗
16. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration10.1073/pnas.1017033108 ↗
17. Bolognesi · 2013
18. Alzheimer's disease: the challenge of the second century10.1126/scitranslmed.3002369 ↗
19. Alzheimer's disease: from pathology to therapeutic approaches10.1002/anie.200802808 ↗
20. Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease10.2174/157488911796958002 ↗
21. Perspectives on inhibiting β-amyloid aggregation through structure-based drug design10.1002/cmdc.201500215 ↗
22. Imaging of β-amyloid plaques by near infrared fluorescent tracers: a new frontier for chemical neuroscienc10.1039/C4CS00337C ↗
23. Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer's disease10.1021/ja405239v ↗
24. The synthesis and evaluation of near-infrared probes with barbituric acid acceptors for in vivo detection of amyloid plaques10.1039/C5CC03662C ↗
25. Development of phenothiazine-based theranostic compounds that act both as inhibitors of β-amyloid aggregation and imaging probes for amyloid plaques in Alzheimer's disease10.1021/acschemneuro.6b00380 ↗
26. Preparing synthetic Aβ in different aggregation states10.1007/978-1-60761-744-0_2 ↗
27. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model10.1016/j.neuroimage.2010.06.020 ↗
28. Imaging multiple phases of neurodegeneration: a novel approach to assessing cell death in vivo10.1038/cddis.2009.3 ↗
29. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo10.1074/jbc.M404751200 ↗
30. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide10.1073/pnas.0911281106 ↗